Clinical trials: Memory Functions
Change in Cognitive Function and Fatigue During Extended Performance of the Cognitive Demand Battery (CDB) at 1, 3 and 6 Hours Post Consumption, Change in Long Term Declarative Memory at 1, 3 and 6 Hours Post-intervention.
Plant Based Extracts and Cognition
Acute, randomized, placebo controlled, double blind, 4 arm crossover study to determine the effect of different combinations of plant based extracts on cognitive function and cerebral blood flow.
- Trial name
- CEOPTB (NCT02202629)
- Testing
- Beverage containing plant based extracts
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- PepsiCo Global R&D
Self-reported Memory Problems, Memory
A Clinical Trial Investigating the Efficacy and Safety of a Lipase Thera-blend and a Lipase Thera-blend + Tributyrin on Memory in Healthy Adults With Self-reported Memory Problems
The goal of this clinical trial is to investigate the efficacy and safety of Lipase Thera-blend and Lipase Thera-blend + tributyrin on memory in healthy adults with self-reported memory problems.
- Trial name
- NCT07020494
- Testing
- Lipase Thera-blend, Lipase Thera-blend + tributyrin
- Where
- Canada
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Enzymedica
Age-Related Memory Disorders
A Study to Evaluate The Effects Of a Multivitamin/Mineral With Ginko In Subjects With Age Associated Memory Impairment
A Study to evaluate the cognitive effects and tolerance of a Multi-Vitamin/Mineral Preperation containing Gingko in elderly subjects with age associated memory impairment.
- Trial name
- NCT01160692
- Testing
- Multivitamin/Multimineral/Ginkgo (BAY 81-2775)
- Where
- United Kingdom
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- Bayer
Platinum-resistant Ovarian Cancer
A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer
This is phase 2 single arm study evaluating the safety and preliminary efficacy of M-CENK adoptive cell therapy and fixed dose of N-803 in combination with gemcitabine in participants with platinum-resistant high-grade ovarian…
- Trial name
- NCT06710288
- Testing
- Gemcitabine, N-803, M-CENK
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- ImmunityBio, Inc.
Hepatitis A, Hepatitis B
Antibody Persistence & Immune Memory in Healthy Adults Previously Vaccinated With Twinrix Adult
This study will evaluate the persistence of the immune response to HAV (Hepatitis A Virus) antigens and HBs (Hepatitis B surface) antigens in healthy adults previously vaccinated with GlaxoSmithKline (GSK) Biologicals' Twinrix…
- Trial name
- NCT01000324
- Testing
- Blood sampling, Engerix-B, Havrix
- Where
- Belgium
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cognitive Impairment, Memory Complaint
Performance of AclarusDx® a Blood-Based Transcriptomic Test for AD, in French Patients Newly Referred to a Memory Center
The purpose of this study is to assess the performance of AclarusDx™, an investigational blood test detecting gene expression information, and intended to help physicians in making an Alzheimer's Disease diagnosis in patients…
- Conditions
- Cognitive Impairment, Memory Complaint, Clinical Investigation in Memory Centers
- Trial name
- DIALOG (NCT02221661)
- Volunteers
- 606 people
- Sponsor
- Diaxonhit
Insomnia
Study of an Evening Dose of Eszopiclone on Next Day Driving Ability & Psychomotor/Memory Function in Healthy Volunteers
Male and female healthy volunteers. Patients must also possess a full current driving license (for at least one year), and be a regular car driver.
- Trial name
- NCT00368160
- Testing
- Eszopiclone
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Sumitomo Pharma America, Inc.
Alzheimer Disease, Dementia of Alzheimer Type
A Study of ATH-1017 in Mild to Moderate Alzheimer's Disease
This study is designed to evaluate treatment effects of ATH-1017 (fosgonimeton) in mild to moderate Alzheimer's subjects with a randomized treatment duration of 26-weeks.
- Trial name
- ACT-AD (NCT04491006)
- Testing
- ATH-1017
- Where
- 13 sites in United States, Australia
- Volunteers
- 77 people
- Sponsor
- LeonaBio
Mild Cognitive Impairment, Alzheimer Disease
Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's Disease
The purpose of this platform study was to evaluate the effect of anti-inflammatory agents on cognition in early Alzheimer's disease.
- Trial name
- NCT04795466
- Testing
- Canakinumab
- Where
- 10 sites in United States, Finland and 2 more
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Neurocognitive Function, Mood
The Effects of 12 Weeks Supplementation With a B-vitamin and Herbal Supplement on Neurocognitive Function and Mood
The aim of the present study is to evaluate chronic supplementation with Swisse Ultiboost Memory + Focus over a 12 week period on memory in individuals with optimal and sub-optimal nutrient profiles.
- Trial name
- MAST (NCT03482063)
- Testing
- Swisse Ultiboost Memory + Focus
- Where
- Australia
- Volunteers
- 141 people, healthy volunteers welcome
- Sponsor
- Swisse Wellness Pty Ltd
Cognitive Function and Memory
Cognitive Effects of a Dietary Supplement With PQQ, GABA, Caffeine, and B-Vitamins in Healthy Postmenopausal Women: A Randomized Controlled Trial
Various food supplements have been shown to improve cognitive function. However, there is limited data on the impact of these supplements on postmenopausal women.
- Trial name
- NCT06748989
- Testing
- Cortexium food supplement
- Where
- Hungary
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- FEMPHARMA Kft.
Schizophrenia
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
This is a study in chronic stable Schizophrenia with the purpose to answer the question of whether agonism of the nicotinic alpha7 receptor is capable of enhancing cognition in a well defined chronic stable patient population…
- Trial name
- NCT01730768
- Testing
- AQW051
- Where
- 13 sites in United States
- Volunteers
- 147 people
- Sponsor
- Novartis Pharmaceuticals
Hepatocellular Carcinoma
NewishT Cell Therapy for HCC With High Risk of Recurrence After Radical Resection
This is a single-arm, open label, multi-center Phase 1 clinical study to evaluate the safety and efficacy of autologous memory lymphocyte therapy (NewishT) in patients with hepatocellular carcinoma at high risk of recurrence…
- Trial name
- NCT05352646
- Testing
- Autologous memory lymphocyte Injection (NewishT), low-dose group, Autologous memory lymphocyte Injection (NewishT), high-dose group
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Newish Technology (Beijing) Co., Ltd.
Dementia, Dementia Alzheimer Type
Plans4Care: Personalized Dementia Care on Demand
The Plans4Care study is a research study funded by the National Institute on Aging (Grant# R44AG084365). The Plans4Care app is designed to help family caregivers address over 90 common care challenges such as behavioral symptoms…
- Conditions
- Dementia, Dementia Alzheimer Type, Alzheimer Dementia (AD), Memory Loss
- Trial name
- NCT07115251
- Testing
- Plans4Care
- Volunteers
- 160 people
- Sponsor
- Plans4Care Inc
Healthy
Efficacy and Safety of Acute Topical and Aromatic Essential Oil-Based Products for Cognitive Support
This study will evaluate whether the InTune product system may help support attention, memory, focus, and other thinking skills in healthy adults ages 18-64.
- Trial name
- ITS (NCT07623811)
- Testing
- Cognitive Support System
- Where
- United States
- Volunteers
- 313 people, healthy volunteers welcome
- Sponsor
- dōTERRA International
Alzheimer Disease
Efficacy and Safety of PRJ212 to Improve the Memory of Patients With Mild Severity Alzheimer's Disease
A 6-month randomized, double-blind and placebo-controlled, followed by a 6-month open label extension study.
- Trial name
- NCT02991235
- Testing
- PRJ212
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Bioiberica
Healthy, Stress
A Clinical Trial to Assess the Effect of AP-Brain Collagen Peptides on the Improvement of Attention, Focus, and Memory in Stressed But Otherwise Healthy Individuals
The goal of this clinical trial is to learn about the effects of AP-Brain collagen peptide on attention, focus, and memory in adults who are stressed but otherwise healthy.
- Trial name
- NCT07572240
- Testing
- AP-Brain Collagen Peptide
- Where
- 8 sites in India
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Rousselot BVBA
Alzheimer Disease
Phase 2 Estimation Study of Fixed Dose Drugs Combination Type of Polypill
This is an estimation-focused Phase 2 study designed to explore and quantify treatment-related changes across multiple clinical outcomes in patients with Alzheimer's disease over a 210-day period.
- Trial name
- NCT06597058
- Testing
- MAR
- Where
- 16 sites in United States
- Volunteers
- 121 people
- Sponsor
- Noah Pharmaceuticals, Inc.
HPV Infection
Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating HPV
Conducting an early phase clinical trial to assess HPV Antigen Presentation Therapeutic Biological Product Mix activity that suggests the potential for clinical benefit of HPV patients. 1.
- Trial name
- 9vHPV-BCG (NCT06959563)
- Testing
- 9vHPV Vaccine plus BCG Vaccine Mix for percutaneous use
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Alzheimer's Disease
The Safety and Efficacy of Neramexane in Patients With Moderate to Severe Alzheimer's Disease
Memory loss and difficulties with thinking associated with Alzheimer's disease may be due to chronic release of a brain chemical called glutamate.
- Trial name
- NCT00090116
- Testing
- Neramexane
- Where
- 34 sites in United States
- Volunteers
- 400 people
- Sponsor
- Forest Laboratories